This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Link between effectiveness and cost data
The costing was carried out retrospectively on the same sample of women enrolled in the clinical trial.
Study sample
The FASTER study included a sample of 38,033 pregnant women. Other details of sample selection were not reported.
Study design
This was a prospective, multi-centre, non-randomised study. The length of follow-up appears to have been the duration of pregnancy. No other details were given.
Analysis of effectiveness
The clinical data used in the analysis were: the risk of DS; the proportion of DS surviving to live birth; the proportion of women who obtained second-trimester screening; the accuracy of screening (sensitivity and false-positive rates); the proportion of women receiving nuchal translucency where appropriate images failed to be obtained or were subsequently rejected; the rate of women who accepted amniocentesis with screen positive; the proportion of women younger than age 35 years who accepted amniocentesis with a positive screening test; the rate of loss from amniocentesis; and the proportion of women with DS who terminated the pregnancy.
Effectiveness results
The risk of DS was 0.002419 in the first trimester (92 cases out of 38,033 pregnancies), 0.002497 in the second trimester (88 cases out of 35,236 pregnancies), and 0.002185 in the third trimester (77 cases out of 35,236 pregnancies).
The proportion of DS surviving to live birth was 0.7027 (26 cases of 37).
The proportion of women who obtained second-trimester screening was 87.9% (92.8% of first-trimester screens). The proportion of women receiving nuchal translucency where appropriate images failed to be obtained was 3.1% at week 10, 2.6% at week 11, 3.2% at week 12, and 5.5% at week 13.
Measure of benefits used in the economic analysis
The summary benefit measure used in the cost-utility analysis was the number of quality-adjusted life-years (QALYs). These were estimated using utility weights derived from the literature and applied to expected survival. The authors stated that utilities associated with a procedural-related loss and the birth of a DS child were derived from a study that used the standard gamble metric. Limited information on the other values was given. The QALYs were discounted at an annual rate of 3%.
Direct costs
The viewpoint of the analysis was not explicitly stated, but it might have been that of society as the societal cost of a DS birth was included in the analysis. The health services considered in the study were the screening tests and the resources associated with pregnancy termination and care for a DS baby. The unit costs of the screening tests, but not the quantities of resources used, were reported. The costs and quantities were estimated using data derived from a review of the literature, no details of which were reported. The price year was 2006. All costs were inflated to 2006 values using the medical component of the Consumer Price Index.
Statistical analysis of costs
The costs appear to have been treated deterministically in the base-case analysis.
Indirect Costs
Productivity costs were not considered.
Currency

US dollars ($).
Sensitivity analysis
A univariate sensitivity analysis was carried out by varying different clinical inputs of the model across the ranges reported in the FASTER trial. A probabilistic Monte Carlo simulation was also performed, in which all of the input distributions were varied simultaneously. Finally, to examine the Stepwise Sequential screening strategy further, false-
